NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

Undervalued ASX healthcare provider

Solid demand profile for global leader.
stocks

SpaceX: What investors need to know about its enormous upcoming IPO

Morningstar launches research coverage of SpaceX.
stocks

Fair value lifts for toll road operator as Aussie fuel supply steadies

An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.0017.100.19%
CAC 408,209.0962.500.77%
DAX 4025,116.86113.820.46%
Dow JONES (US)51,219.02140.140.27%
FTSE 10010,373.5134.560.33%
HKSE26,038.32640.142.52%
NASDAQ27,138.7951.980.19%
Nikkei 22566,734.24200.09-0.30%
NZX 50 Index13,170.7173.84-0.56%
S&P 5007,613.5013.540.18%
S&P/ASX 2008,724.4017.700.20%
SSE Composite Index4,075.1017.360.43%

Market Movers